It is of great importance for patients to be evaluated by a multidisciplinary team including oncologists, cardiologists, and pharmacologists, for protecting patients from possible CDK4/6 inhibitor cardiotoxicity and improving patients’ quality of life, while receiving the best possible cancer treatment. This evidence concerns the gene CDK4 and cancer.